However, the yield of cell-free DNA may be useful in this regard: in the ctcDNA-based NGS assay, one of the four patients with tumor tissue KRAS mutations not present in the plasma had a low yield of cfDNA, suggestive of technological limitations. This evidence concerns the gene KRAS and neoplasm.